Cetuximab | C225 | EGFR Inhibitor | AmBeed-信号通路专用抑制剂

Cetuximab/西妥昔单抗 {[allProObj[0].p_purity_real_show]}

货号：A879617 同义名： C225

Cetuximab是一种嵌合IgG1单克隆抗体，通过与EGFR胞外结构域结合来阻止其与配体结合。Cetuximab具有用于头颈部鳞状细胞癌和结直肠癌研究的潜力。

Cetuximab/西妥昔单抗化学结构
CAS号：205923-56-4

Cetuximab/西妥昔单抗 3D分子结构
CAS号：205923-56-4

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

EGFR 亚型比较

产品名称	EGFR/ErbB1 ↓ ↑	ErbB3 ↓ ↑	ErbB4 ↓ ↑	HER2/ErbB2 ↓ ↑	mutant EGFR ↓ ↑	其他靶点	纯度
WZ-3146	++++ EGFR (E746_A750), IC50: 2 nM EGFR (E746_A750/T790M), IC50: 14 nM						99%+
Daphnetin	+ EGFR, IC50: 7.67 μM					PKA,PKC	95%
Lifirafenib	++ EGFR, IC50: 29 nM				+ EGFR(T790M/L858R), IC50: 495 nM		98%
PD168393	++++ EGFR, IC50: 0.70 nM						99%+
Nazartinib	++ mutant EGFR, Ki: 0.031 μM				++ mutant EGFR, Ki: 0.031 μM		98%
Norcantharidin	✔						98%
CL-387785	++++ EGFR, IC50: 370 pM						98%
WHI-P154	+++ EGFR, IC50: 4 nM					Src,VEGFR	98%
Tyrphostin A9	+ EGFR, IC50: 460 μM					PDGFR	98%
AG 555	+ EGFR, IC50: 0.7 μM						98%
AG 494	+ EGFR, IC50: 1.2 μM						99%+
AG-556	+ EGFR, IC50: 5 μM						98%
RG13022	+ EGFR, IC50: 4 μM						99%+
Tyrphostin RG 14620	✔						99%+
Vandetanib	+ EGFR, IC50: 500 nM						99%
CNX-2006	++ mutant EGFR, IC50: <20 nM				++ mutant EGFR, IC50: <20 nM		99%
AZD3759	++++ EGFR (L858R), IC50: 0.2 nM EGFR (WT), IC50: 0.3 nM						98%
Erlotinib	++++ EGFR, IC50: 2 nM						95%
Saracatinib	+++ EGFR (L861Q), IC50: 4 nM EGFR, IC50: 5 nM						99%+
AG1557	✔						99%
Rociletinib	++ EGFR (L858R/T790M), Ki: 21.5 nM EGFR (wt), Ki: 303.3 nM						98%
AG490	+ EGFR, IC50: 0.1 μM						98%
Cetuximab	++++ EGFR, Kd: 0.39 nM						95%
Osimertinib	++ WT EGFR, IC50: 12.92 nM L858R/T790M EGFR, IC50: 11.44 nM						98%
Osimertinib mesylate	✔						98% (Content MsOH 15.2-18.2%)
Chrysophanol	✔					mTOR	98%
PD153035	++++ EGFR, Ki: 5.2 pM						99%+
Olmutinib	✔					BTK	99%+
WZ4002	++++ EGFR (L858R/T790M), IC50: 8 nM EGFR (L858R), IC50: 2 nM						99%+
Icotinib	+++ EGFR, IC50: 5 nM						99%
Desmethyl Erlotinib HCl	++++ EGFR, IC50: 2 nM						98%
Cyasterone	✔						99%+
PP 3	+ EGFR tyrosine kinase, IC50: 2.7 μM						98%
WZ8040	✔						99%+
(-)-Epigallocatechin Gallate	✔						99%
AG 18	+ EGFR, IC50: 35 μM						99%+
O-Desmethyl gefitinib	++ EGFR, IC50: 36 nM						99%
Falnidamol	✔						99%+
AZ-5104	++++ EGFR (L858R), IC50: 6 nM EGFR (L861Q) , IC50: <1 nM		+++ ErbB4, IC50: 7 nM			BRK	99%+
Butein	✔						95%
Genistein	✔						98%
SU5214	+ EGFR, IC50: 36.7 μM						99%+
Naquotinib	✔						99%+
Gefitinib	++ EGFR, IC50: 15.5 nM				+ EGFR (858R/T790M), IC50: 823.3 nM		98%
Theliatinib	+++ WT EGFR, IC50: 3 nM				++ EGFR T790M/L858R, IC50: 22 nM		99%
Lazertinib	++++ WT EGFR, IC50: 76 nM L858R/T790M EGFR, IC50: 2 nM				++++ Del19/T790M, IC50: 1.7 nM		99%+
Gefitinib-based PROTAC 3	++ EGFR, DC50: 22.3 nM						99%+
MTX-211	✔					PI3K	98%
(E)-AG 99	✔						99%+
Licochalcone D	✔					PARP,Caspase	99%
Zipalertinib	+++ EGFR WT, IC50: 8 nM EGFR (L861Q), IC50: 4.1 nM		+++ HER4, IC50: 4 nM		++++ EGFR(d746-750), IC50: 1.4 nM EGFR L858R, IC50: 2 nM		97%
JND3229	+++ EGFR WT, IC50: 6.8 nM				++ EGFR L858R/T790M, IC50: 30.5 nM		99%+
Firmonertinib mesylate	✔						99%+
Tyrphostin AG30	✔						99%+
EGFR-IN-12	++ EGFR, IC50: 21 nM						99%+
Mobocertinib	✔						98%
(Rac)-JBJ-04-125-02	✔						95%
(S)-Sunvozertinib	✔						99%
BLU-945	✔						95%
Poziotinib	+++ HER1, IC50: 3.2 nM		++ HER4, IC50: 23.5 nM	+++ HER2, IC50: 5.3 nM			98%
TAK-285	++ EGFR/HER1, IC50: 23 nM		+ HER4, IC50: 260 nM	++ HER2, IC50: 17 nM			99%+
ARRY-380 analog				✔			99%
Canertinib	++++ EGFR, IC50: 1.5 nM			+++ ErbB2, IC50: 9.0 nM			99%+
Dacomitinib	+++ EGFR, IC50: 6.0 nM		+ ErbB4, IC50: 73.7 nM	+ ErbB2, IC50: 45.7 nM			98%
EGFR/ErbB-2/ErbB-4 inhibitor-2			+ ErbB4, IC50: 1.91 μM	+ ErbB2, IC50: 0.08 μM			99%+
(E/Z)-CP-724714				++ HER2/ErbB2, IC50: 10 nM			95%
Lapatinib	++ EGFR, IC50: 10.8 nM		+ ErbB4, IC50: 367 nM	+++ ErbB2, IC50: 9.2 nM			98%
AEE788	++++ EGFR, IC50: 2 nM		+ HER4/ErbB4, IC50: 160 nM	+++ HER2/ErbB2, IC50: 6 nM		c-Fms/CSF1R	98+%
AV-412 free base	++++ EGFR, IC50: 0.75 nM			++ ErbB2, IC50: 19 nM	++++ EGFR^L858R/T790M, IC50: 0.51 nM EGFR^T790M, IC50: 0.79 nM		98+%
Neratinib	+ EGFR, IC50: 92 nM			+ HER2, IC50: 59 nM		Src	98%
BMS-599626	++ HER1, IC50: 20 nM		+ HER4, IC50: 190 nM	++ HER2, IC50: 30 nM			98%
Tucatinib				+++ ErbB2, IC50: 8 nM			98%
Allitinib	++++ EGFR, IC50: 0.5 nM		++++ ErbB4, IC50: 0.8 nM	+++ ErbB2, IC50: 3.0 nM			99%
Pelitinib	+ EGFR, IC50: 38.5 nM			+ ErbB2, IC50: 1.255 μM		Src,Raf	99%+
Sapitinib	+++ EGFR, IC50: 4 nM	+++ ErbB3, IC50: 4 nM		+++ ErbB2, IC50: 3 nM			99%+
CUDC-101	+++ EGFR, IC50: 2.4 nM			++ HER2, IC50: 15.7 nM		HDAC	99%+
Varlitinib	+++ ErbB1, IC50: 7 nM			++++ ErbB2, IC50: 2 nM			99%+
Afatinib dimaleate	++++ EGFR (L858R/T790M), IC50: 0.4 nM EGFR (wt), IC50: 0.5 nM			++ HER2, IC50: 14 nM			98%
Canertinib 2HCl	+++ EGFR, IC50: 7.4 nM			+++ ErbB2, IC50: 9 nM			99%
Allitinib tosylate	++++ EGFR (T790M/L858R), IC50: 12 nM EGFR, IC50: 0.5 nM		++++ ErbB4, IC50: 0.8 nM	+++ ErbB2, IC50: 3.0 nM			99%
Tyrphostin AG 528	+ EGFR, IC50: 4.9 μM			+ HER2, IC50: 2.1 μM			97%
Afatinib	++++ EGFR (wt), IC50: 0.5 nM EGFR (L858R), IC50: 10 nM		++++ ErbB4, IC50: 1 nM	++ HER2, IC50: 14 nM			99%
Pyrotinib dimaleate	++ EGFR, IC50: 0.013 μM			++ HER2, IC50: 0.038 μM			98%
Epertinib HCl	++++ EGFR, IC50: 1.48 nM		+++ HER4, IC50: 2.49 nM	+++ HER2, IC50: 7.15 nM			99%
Tuxobertinib	++++ EGFR, Kd: 0.2 nM			++++ HER2, Kd: 0.76 nM			99%
ALK-IN-1					++ EGFR(del19), IC50: 36.8 nM EGFR(C797S/del19), IC50: 138.6 nM	ALK	99%
Brigatinib					+ EGFR(C797S/T790M/del19), IC50: 67.2 nM EGFR(del19), IC50: 39.9 nM	ALK,FLT3	98%
Avitinib					++++ EGFR L858R/T790M, IC50: 0.18 nM	BTK	99%+
EAI045					✔		97%
Almonertinib					✔		99%
BI-4020					++++ EGFR^{del19 T790M C797S}, IC50: 0.2 nM		99%+
EGFR-IN-7					++++ EGFR^L858R/T790M, IC50: 0.19 nM EGFR^{d746-750/T790M/C797S}, IC50: 0.26 nM		99%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Cetuximab/西妥昔单抗生物活性

靶点

EGFR/ErbB1

EGFR, Kd:0.39 nM

蛋白种属

Human

交叉反应性

Human,Mouse,Cynomolgus

Isotype

IgG1-Kappa

内毒素

< 0.001EU/μg, determined by LAL method.

纯化方法

Purified, Protein A, affinity column

稀释缓冲液

Sterile PBS or 0.9% saline for reconstitution/dilution. It is recommended to use the reconstituted/diluted product within one month.

Cetuximab/西妥昔单抗细胞实验

Cell Line NK cells IL-1R1 stable knockdown SQ20B cells MyD88 stable knockdown SQ20B cells SQ20B cells Cal-27 cells DLD-1 HCT116 C10 SW48 HCT116 cells H1975 cells UMSCC 103 Patient-derived colorectal cancer organoids (PDXO) Patient-derived colorectal cancer organoids (PDXO)	Concentration	Treated Time	Description	References
NK cells	10 μg/mL	24 hours	To evaluate the killing effect of NK cells on HNSCC cells in the presence of Lirilumab, results showed that Lirilumab significantly enhanced NK cell-mediated killing of tumor cells.	Head Neck. 2019 Aug;41(8):2591-2601
IL-1R1 stable knockdown SQ20B cells	1, 10, and 100 μg/mL	48 h	IL-1R1 knockdown significantly suppressed cetuximab-induced cytokine secretion.	J Immunother Cancer. 2019 Mar 19;7(1):79
MyD88 stable knockdown SQ20B cells	1, 10, and 100 μg/mL	48 h	MyD88 knockdown significantly suppressed cetuximab-induced cytokine secretion.	J Immunother Cancer. 2019 Mar 19;7(1):79
SQ20B cells	1, 10, and 100 μg/mL	48 h	Cetuximab at a dose of 100 μg/mL significantly increased IL-1α and IL-8 secretion, and increased IL-6 secretion at all tested concentrations.	J Immunother Cancer. 2019 Mar 19;7(1):79
Cal-27 cells	1, 10, and 100 μg/mL	48 h	Cetuximab at a dose of 100 μg/mL significantly increased IL-1α, IL-6, and IL-8 secretion.	J Immunother Cancer. 2019 Mar 19;7(1):79
DLD-1	100 μg/ml	24 h	To evaluate the cytotoxic and antiproliferative effects of Cetuximab combined with RSL3 on KRAS mutant CRC cells. Results showed that the combination treatment significantly inhibited cell viability and proliferation.	Cell Death Dis. 2021 Nov 13;12(11):1079
HCT116	100 μg/ml	24 h	To evaluate the cytotoxic and antiproliferative effects of Cetuximab combined with RSL3 on KRAS mutant CRC cells. Results showed that the combination treatment significantly inhibited cell viability and proliferation.	Cell Death Dis. 2021 Nov 13;12(11):1079
C10	1 ng/µL	72 h	To assess the efficacy of targeting the AURKA/YAP1 axis to overcome cetuximab resistance	Br J Cancer. 2024 May;130(8):1402-1413
SW48	10 ng/µL	72 h	To assess the efficacy of targeting the AURKA/YAP1 axis to overcome cetuximab resistance	Br J Cancer. 2024 May;130(8):1402-1413
HCT116 cells	0.1 μM or 1 μM	24 h	To evaluate the effect of Cetuximab on EGFR protein expression. Results showed that Cetuximab only marginally affected EGFR levels in HCT116 cells.	J Nucl Med. 2018 Oct;59(10):1558-1565
H1975 cells	0.1 μM or 1 μM	24 h	To evaluate the effect of Cetuximab on EGFR protein expression. Results showed that 0.1 μM Cetuximab reduced EGFR protein expression by 3-fold in H1975 cells, while the effect was slightly attenuated at the higher dose (1 μM).	J Nucl Med. 2018 Oct;59(10):1558-1565
UMSCC 103	20 μM	48 h	Test the cytotoxic effect of Cetuximab on UMSCC 103, finding significant cell death when combined with ICI	Cell Death Dis. 2023 Sep 19;14(9):613
Patient-derived colorectal cancer organoids (PDXO)	20 μg/mL	72 h	To evaluate the effect of cetuximab on BIM protein expression, results showed that cetuximab upregulated BIM protein levels.	Clin Cancer Res. 2023 Mar 14;29(6):1102-1113
Patient-derived colorectal cancer organoids (PDXO)	20 μg/mL	1 week	To evaluate the effect of cetuximab on PDXO cell viability, results showed that cetuximab inhibited cell growth.	Clin Cancer Res. 2023 Mar 14;29(6):1102-1113

Cell Line

Concentration

Treated Time

Description

References

NK cells

10 μg/mL

24 hours

To evaluate the killing effect of NK cells on HNSCC cells in the presence of Lirilumab, results showed that Lirilumab significantly enhanced NK cell-mediated killing of tumor cells.

Head Neck. 2019 Aug;41(8):2591-2601

IL-1R1 stable knockdown SQ20B cells

1, 10, and 100 μg/mL

48 h

IL-1R1 knockdown significantly suppressed cetuximab-induced cytokine secretion.

J Immunother Cancer. 2019 Mar 19;7(1):79

MyD88 stable knockdown SQ20B cells

1, 10, and 100 μg/mL

48 h

MyD88 knockdown significantly suppressed cetuximab-induced cytokine secretion.

J Immunother Cancer. 2019 Mar 19;7(1):79

SQ20B cells

1, 10, and 100 μg/mL

48 h

Cetuximab at a dose of 100 μg/mL significantly increased IL-1α and IL-8 secretion, and increased IL-6 secretion at all tested concentrations.

J Immunother Cancer. 2019 Mar 19;7(1):79

Cal-27 cells

1, 10, and 100 μg/mL

48 h

Cetuximab at a dose of 100 μg/mL significantly increased IL-1α, IL-6, and IL-8 secretion.

J Immunother Cancer. 2019 Mar 19;7(1):79

DLD-1

100 μg/ml

24 h

To evaluate the cytotoxic and antiproliferative effects of Cetuximab combined with RSL3 on KRAS mutant CRC cells. Results showed that the combination treatment significantly inhibited cell viability and proliferation.

Cell Death Dis. 2021 Nov 13;12(11):1079

HCT116

100 μg/ml

24 h

Cell Death Dis. 2021 Nov 13;12(11):1079

C10

1 ng/µL

72 h

To assess the efficacy of targeting the AURKA/YAP1 axis to overcome cetuximab resistance

Br J Cancer. 2024 May;130(8):1402-1413

SW48

10 ng/µL

72 h

To assess the efficacy of targeting the AURKA/YAP1 axis to overcome cetuximab resistance

Br J Cancer. 2024 May;130(8):1402-1413

HCT116 cells

0.1 μM or 1 μM

24 h

To evaluate the effect of Cetuximab on EGFR protein expression. Results showed that Cetuximab only marginally affected EGFR levels in HCT116 cells.

J Nucl Med. 2018 Oct;59(10):1558-1565

H1975 cells

0.1 μM or 1 μM

24 h

To evaluate the effect of Cetuximab on EGFR protein expression. Results showed that 0.1 μM Cetuximab reduced EGFR protein expression by 3-fold in H1975 cells, while the effect was slightly attenuated at the higher dose (1 μM).

J Nucl Med. 2018 Oct;59(10):1558-1565

UMSCC 103

20 μM

48 h

Test the cytotoxic effect of Cetuximab on UMSCC 103, finding significant cell death when combined with ICI

Cell Death Dis. 2023 Sep 19;14(9):613

Patient-derived colorectal cancer organoids (PDXO)

20 μg/mL

72 h

To evaluate the effect of cetuximab on BIM protein expression, results showed that cetuximab upregulated BIM protein levels.

Clin Cancer Res. 2023 Mar 14;29(6):1102-1113

Patient-derived colorectal cancer organoids (PDXO)

20 μg/mL

1 week

To evaluate the effect of cetuximab on PDXO cell viability, results showed that cetuximab inhibited cell growth.

Clin Cancer Res. 2023 Mar 14;29(6):1102-1113

Cetuximab/西妥昔单抗动物实验

Species Athymic nu/nu mice BALB/c nude mice Mice Nude mice BALB/c nude mice NSG mice NOD/SCID mice	Animal Model Cal-27 and SQ20B xenograft models DLD-1 xenograft model Patient-derived xenograft (PDX) models of KRAS-mutated colorectal cancer Orthotopic HNSCC mouse model H1975 tumor model (non-small cell lung cancer) and HCT116 tumor model (colorectal cancer) CDX-humanized mouse model Patient-derived xenograft models (PDX)	Administration	Dosage	Frequency	Description	References
Athymic nu/nu mice	Cal-27 and SQ20B xenograft models	Intraperitoneal injection	2 mg/kg	Twice weekly for 2 weeks	IL-1 blockade (using anakinra) did not affect the anti-tumor efficacy of cetuximab.	J Immunother Cancer. 2019 Mar 19;7(1):79
BALB/c nude mice	DLD-1 xenograft model	Intraperitoneal injection	13 mg/kg	Once daily for 17 days	To evaluate the antitumor effects of Cetuximab combined with RSL3 on KRAS mutant CRC xenograft models. Results showed that the combination treatment significantly reduced tumor volume and increased MDA levels.	Cell Death Dis. 2021 Nov 13;12(11):1079
Mice	Patient-derived xenograft (PDX) models of KRAS-mutated colorectal cancer	Intraperitoneal injection	25 mg/kg	Twice weekly, for 28 days or longer	To evaluate the efficacy of combined Cetuximab and Trametinib therapy in KRAS-mutated CRC PDX models. The combination therapy induced disease control (partial response or stable disease) in 74% of the models analyzed, with 47% achieving partial response.	Mol Oncol. 2023 Nov;17(11):2396-2414
Nude mice	Orthotopic HNSCC mouse model	Intraperitoneal injection	40 mg/kg	Every 3 days for 4 weeks	Evaluate the effect of Cetuximab alone or in combination with ICI on HNSCC tumor growth, finding significant tumor growth delay with combination therapy	Cell Death Dis. 2023 Sep 19;14(9):613
BALB/c nude mice	H1975 tumor model (non-small cell lung cancer) and HCT116 tumor model (colorectal cancer)	Intravenous injection (Cetuximab) or intraperitoneal injection (Gemcitabine)	10 mg/kg	Cetuximab was administered on day 1 or days 1 and 2, Gemcitabine on day 2, and imaging was performed on day 3.	To evaluate the effect of Cetuximab alone or in combination with Gemcitabine on tumor growth and biological markers. Results showed that repeated doses of Cetuximab significantly increased 18F-ICMT-11 uptake and cleaved caspase-3 staining in H1975 tumors, while a single dose was insufficient to induce apoptosis but affected proliferation. 18F-FLT uptake was significantly reduced, paralleled by a decrease in Ki-67 and marked tumor growth delay. HCT116 tumors were insensitive to Cetuximab treatment.	J Nucl Med. 2018 Oct;59(10):1558-1565
NSG mice	CDX-humanized mouse model	Intravenous injection	0.4 mg/kg/dose	Weekly for 5 weeks	Evaluate the antitumor effects of cetuximab in combination with NK cells	J Immunother Cancer. 2024 Mar 27;12(3):e008585
NOD/SCID mice	Patient-derived xenograft models (PDX)	Intraperitoneal injection	20 mg/kg	Twice weekly for 5 weeks	To evaluate the effect of cetuximab on tumor volume in PDX models, results showed that cetuximab significantly reduced tumor volume.	Clin Cancer Res. 2023 Mar 14;29(6):1102-1113

Species

Athymic nu/nu mice BALB/c nude mice Mice Nude mice BALB/c nude mice NSG mice NOD/SCID mice

Animal Model

Cal-27 and SQ20B xenograft models DLD-1 xenograft model Patient-derived xenograft (PDX) models of KRAS-mutated colorectal cancer Orthotopic HNSCC mouse model H1975 tumor model (non-small cell lung cancer) and HCT116 tumor model (colorectal cancer) CDX-humanized mouse model Patient-derived xenograft models (PDX)

Administration

Dosage

Frequency

Description

References

Athymic nu/nu mice

Cal-27 and SQ20B xenograft models

Intraperitoneal injection

2 mg/kg

Twice weekly for 2 weeks

IL-1 blockade (using anakinra) did not affect the anti-tumor efficacy of cetuximab.

J Immunother Cancer. 2019 Mar 19;7(1):79

BALB/c nude mice

DLD-1 xenograft model

Intraperitoneal injection

13 mg/kg

Once daily for 17 days

To evaluate the antitumor effects of Cetuximab combined with RSL3 on KRAS mutant CRC xenograft models. Results showed that the combination treatment significantly reduced tumor volume and increased MDA levels.

Cell Death Dis. 2021 Nov 13;12(11):1079

Mice

Patient-derived xenograft (PDX) models of KRAS-mutated colorectal cancer

Intraperitoneal injection

25 mg/kg

Twice weekly, for 28 days or longer

To evaluate the efficacy of combined Cetuximab and Trametinib therapy in KRAS-mutated CRC PDX models. The combination therapy induced disease control (partial response or stable disease) in 74% of the models analyzed, with 47% achieving partial response.

Mol Oncol. 2023 Nov;17(11):2396-2414

Nude mice

Orthotopic HNSCC mouse model

Intraperitoneal injection

40 mg/kg

Every 3 days for 4 weeks

Evaluate the effect of Cetuximab alone or in combination with ICI on HNSCC tumor growth, finding significant tumor growth delay with combination therapy

Cell Death Dis. 2023 Sep 19;14(9):613

BALB/c nude mice

H1975 tumor model (non-small cell lung cancer) and HCT116 tumor model (colorectal cancer)

Intravenous injection (Cetuximab) or intraperitoneal injection (Gemcitabine)

10 mg/kg

Cetuximab was administered on day 1 or days 1 and 2, Gemcitabine on day 2, and imaging was performed on day 3.

To evaluate the effect of Cetuximab alone or in combination with Gemcitabine on tumor growth and biological markers. Results showed that repeated doses of Cetuximab significantly increased 18F-ICMT-11 uptake and cleaved caspase-3 staining in H1975 tumors, while a single dose was insufficient to induce apoptosis but affected proliferation. 18F-FLT uptake was significantly reduced, paralleled by a decrease in Ki-67 and marked tumor growth delay. HCT116 tumors were insensitive to Cetuximab treatment.

J Nucl Med. 2018 Oct;59(10):1558-1565

NSG mice

CDX-humanized mouse model

Intravenous injection

0.4 mg/kg/dose

Weekly for 5 weeks

Evaluate the antitumor effects of cetuximab in combination with NK cells

J Immunother Cancer. 2024 Mar 27;12(3):e008585

NOD/SCID mice

Patient-derived xenograft models (PDX)

Intraperitoneal injection

20 mg/kg

Twice weekly for 5 weeks

To evaluate the effect of cetuximab on tumor volume in PDX models, results showed that cetuximab significantly reduced tumor volume.

Clin Cancer Res. 2023 Mar 14;29(6):1102-1113

Cetuximab/西妥昔单抗技术信息

CAS号	205923-56-4
分子量	145.56 kDa
SMILES Code	NONE
MDL No.	MFCD06407972

别名	C225
运输	蓝冰

存储条件	In solvent -20°C:3-6个月-80°C:24个月

Cetuximab/西妥昔单抗 {[allProObj[0].p_purity_real_show]}

Cetuximab/西妥昔单抗纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Cetuximab/西妥昔单抗质控信息

Cetuximab/西妥昔单抗生物活性

Cetuximab/西妥昔单抗细胞实验

Cetuximab/西妥昔单抗动物实验

Cetuximab/西妥昔单抗技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Cetuximab/西妥昔单抗 {[allProObj[0].p_purity_real_show]}

Cetuximab/西妥昔单抗 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Cetuximab/西妥昔单抗 质控信息

Cetuximab/西妥昔单抗 生物活性

Cetuximab/西妥昔单抗 细胞实验

Cetuximab/西妥昔单抗 动物实验

Cetuximab/西妥昔单抗 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Cetuximab/西妥昔单抗纯度/质量文件产品仅供科研

Cetuximab/西妥昔单抗质控信息

Cetuximab/西妥昔单抗生物活性

Cetuximab/西妥昔单抗细胞实验

Cetuximab/西妥昔单抗动物实验

Cetuximab/西妥昔单抗技术信息